A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy
Shigeru Kinoshita, Kathryn Colby, Friedrich E. Kruse
Abstract
ABSTRACT: The current understanding on the clinical efficacy of Rho-associated protein kinase (ROCK) inhibitor for treating Fuchs endothelial corneal dystrophy is summarized to clarify whether the "off-label" ROCK-inhibitor eye-drop application are appropriate. ROCK-inhibitor eye drops may eventually be deemed a cutting-edge therapy for Fuchs endothelial corneal dystrophy patients with acute corneal endothelial defect.
Topics & Concepts
DystrophyOphthalmologyMedicineCorneaPathologyCorneal surgery and disordersGlaucoma and retinal disordersCorneal Surgery and Treatments